Two Executives Named To Bellrock Board
PITTSBURGH, Sept. 14, 2017 /PRNewswire/ -- William Pocklington, an experienced healthcare executive, and Paul Schmitt, a noted venture capitalist, have been named to the Board of Directors (www.BellrockIntel.com/leadership.html) of Bellrock Intelligence, it was announced today by Bellrock Board Chairman Robert Rittereiser. Bellrock is a SaaS decision support company whose enterprise intelligence platform is based on intelligence sector know-how. Its customized advanced analytics link internal and institutional data with relevant external information to provide actionable strategic intelligence for executives, physicians and managers that enables them to make better clinical, business and population health decisions.
Pocklington and Schmitt join Dr. Nir Kossovsky and Alfred Fasola on the Bellrock Board. In making the announcement, Rittereiser said, "These two accomplished and highly respected executives further strengthen our Board as we introduce our cutting-edge proprietary technology that will revolutionize healthcare decision-making and significantly improve clinical outcomes and patient satisfaction while lowering costs."
Pocklington, an independent business advisor and investor, most recently was Vice President at Change Healthcare, one of the largest and most innovative independent healthcare technology companies in the U.S. Previously he was Vice President of Sales at McKesson Health Solutions where he led sales for the Eastern Region for the company's Financial Management and Network Management product lines.
He was a founder of Portico Systems and led sales and business development, including strategic alliances. Prior to joining Portico Systems, Pocklington for over 20 years led sales, business development, consulting services and marketing for Strategic Management Group, Inc., a computer-based business simulation software company. He is an advisor and investor in Clarip, Kognition and Smarter Services and serves on the Boards of the Global Neurosciences Foundation and Friends of the Manor.
Over 35 years, Schmitt has built a successful track record of building companies and commercializing complex, regulated life science technologies, primarily in collaboration with major universities and academic medical centers.
As a CEO and investor, he has spearheaded the formation and growth of two public and three private companies. He has raised over $500 million in growth capital financings and has led numerous transactions including IPOs, mergers, acquisitions, divestitures, licenses and joint ventures. A trustee of the Wistar Institute in Philadelphia, he also serves on the boards of GelMed Sciences, JBS United Animal Health JV, Cernostics (Chairman) and as the Amorcyte shareholder representative to Caladrius.
(For more information: BellrockIntel.com)
SOURCE Bellrock Intelligence
Share this article